Dyne Depreciation And Amortization from 2010 to 2024
| DYN Stock | USD 29.73 0.26 0.87% |
Depreciation And Amortization | First Reported 2007-06-30 | Previous Quarter 399 K | Current Value 438 K | Quarterly Volatility 79.3 M |
Check Dyne Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Dyne Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.6 M, Interest Expense of 2.5 M or Selling General Administrative of 29.8 M, as well as many indicators such as Price To Sales Ratio of 6.54, Dividend Yield of 0.0 or PTB Ratio of 9.13. Dyne financial statements analysis is a perfect complement when working with Dyne Therapeutics Valuation or Volatility modules.
Dyne | Depreciation And Amortization |
Latest Dyne Therapeutics' Depreciation And Amortization Growth Pattern
Below is the plot of the Depreciation And Amortization of Dyne Therapeutics over the last few years. It is the systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives. Dyne Therapeutics' Depreciation And Amortization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Dyne Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Depreciation And Amortization | 10 Years Trend |
|
Depreciation And Amortization |
| Timeline |
Dyne Depreciation And Amortization Regression Statistics
| Arithmetic Mean | 247,799,690 | |
| Coefficient Of Variation | 124.34 | |
| Mean Deviation | 260,053,623 | |
| Median | 26,000,000 | |
| Standard Deviation | 308,106,558 | |
| Sample Variance | 94929.7T | |
| Range | 867.8M | |
| R-Value | (0.48) | |
| Mean Square Error | 78774.2T | |
| R-Squared | 0.23 | |
| Significance | 0.07 | |
| Slope | (33,001,677) | |
| Total Sum of Squares | 1329015.1T |
Dyne Depreciation And Amortization History
About Dyne Therapeutics Financial Statements
Dyne Therapeutics investors utilize fundamental indicators, such as Depreciation And Amortization, to predict how Dyne Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Depreciation And Amortization | 1.7 M | 1.6 M |
Pair Trading with Dyne Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dyne Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dyne Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Dyne Stock
Moving against Dyne Stock
| 0.71 | PRAX | Praxis Precision Med | PairCorr |
| 0.69 | AMLX | Amylyx Pharmaceuticals | PairCorr |
| 0.61 | VRDN | Viridian Therapeutics | PairCorr |
| 0.59 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.54 | AKRO | Akero Therapeutics | PairCorr |
The ability to find closely correlated positions to Dyne Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dyne Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dyne Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dyne Therapeutics to buy it.
The correlation of Dyne Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dyne Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dyne Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dyne Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Dyne Therapeutics Correlation against competitors. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.62) | Return On Assets (0.40) | Return On Equity (0.69) |
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.